CSL chief financial officer Ken Lim says the global healthcare giant is trying to simplify its organisation after conceding that a slowdown in its ability to make quick decisions had hurt its ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...

CSL Behring announced a $1.5 billion expansion to its Bourbonnais Township plant, which would add about 300-400 jobs. The company plans to break ground this summer and have the expansion fully ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...

Eli Lilly inked another deal in the anti-inflammatory space, agreeing to pay CSL Ltd. $100 million to license a monoclonal antibody that targets interleukin-6 (IL-6). Under the agreement announced ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

SYDNEY--Australia-based pharmaceutical company CSL said that Chief Executive Paul McKenzie will retire after a three-year tenure. CSL said that Gordon Naylor, a highly experienced former CSL senior ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...